Antibody Therapeutics (IF=4.8, Oxford University Press) ⚡ Review Highlight -Ivonescimab and other anti-programmed death-1/ligand 1 (PD-(L)1)/vascular endothelial growth factor (VEGF) bispecific antibodies: progress and prospects in cancer therapy.
doi.org/10.1093/abt/...
#mabs

Antibody Therapeutics (IF=4.8, Oxford University Press) ⚡ Review Highlight -CAR NK cell therapy for solid tumors: potential and challenges
doi.org/10.1093/abt/...
#mab #mabs #antibody #antibodies #antibodydiscovery #antibodytherapeutics #biologics #naturalkillercells #CAR #CARNK

Antibody Therapeutics (IF=4.8, Oxford University Press) ⚡ Research Highlight - ACE2-Fc and DPP4-Fc decoy receptors against SARS-CoV-2 and MERS-CoV variants: a quick therapeutic option for current and future coronaviruses outbreaks.
doi.org/10.1093/abt/...
#immunoadhesins #mabs

Antibody Therapeutics (IF=4.8, Oxford University Press) ⚡ Research Highlight -Preclinical development of mecbotamab vedotin (BA3011), a novel, AXL-specific conditional active biologic antibody–drug conjugate.
doi.org/10.1093/abt/...
#mabs #antibody #antibodies #antibodydiscovery

Antibody Therapeutics (IF=4.8, Oxford University Press) ⚡ Research Highlight -First site-specific conjugation method for native goat IgG antibodies via glycan remodeling at the conserved Fc region.
doi.org/10.1093/abt/...
#mabs #antibody #antibodydiscovery #antibodytherapeutics